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The endogenous double-stranded RNA (dsRNA) virus Leishmaniavirus
(LRV1) has been implicated as a pathogenicity factor for leishmaniasis
in rodent models and human disease, and associatedwith drug-treat-
ment failures in Leishmania braziliensis and Leishmania guyanensis
infections. Thus, methods targeting LRV1 could have therapeutic ben-
efit. Here we screened a panel of antivirals for parasite and LRV1
inhibition, focusing on nucleoside analogs to capitalize on the highly
active salvage pathways of Leishmania, which are purine auxo-
trophs. Applying a capsid flow cytometry assay, we identified two
2′-C-methyladenosine analogs showing selective inhibition of LRV1.
Treatment resulted in loss of LRV1 with first-order kinetics, as
expected for random virus segregation, and elimination within six
cell doublings, consistent with a measured LRV1 copy number of
about 15. Viral loss was specific to antiviral nucleoside treatment
and not induced by growth inhibitors, in contrast to fungal dsRNA
viruses. Comparisons of drug-treated LRV1+ and LRV1− lines recapit-
ulated LRV1-dependent pathology and parasite replication in mouse
infections, and cytokine secretion in macrophage infections. Agents
targeting Totiviridae have not been described previously, nor are
there many examples of inhibitors acting against dsRNA viruses more
generally. The compounds identified here provide a key proof-of-
principle in support of further studies identifying efficacious antivi-
rals for use in in vivo studies of LRV1-mediated virulence.
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Protozoan parasites of the genus Leishmania are responsiblefor leishmaniasis in many regions of the world, with 12 million
current cases (accompanied by at least 10-fold more bearing
asymptomatic infections) and nearly 1.7 billion people at risk (1–5).
The disease has three predominant clinical manifestations, ranging
from the relatively mild, self-healing cutaneous form, to mucocuta-
neous lesions where parasites metastasize to and cause destruction
of mucous membranes of the nose, mouth, and throat, or fatal
visceral disease. Disease phenotypes segregate primarily with
the infecting species; however, it is not fully understood which
parasite factors affect severity and disease manifestations.
One recently identified parasite factor contributing to disease se-
verity in several Leishmania species is the RNA virus Leishmaniavirus
(6, 7). These endobiont viruses classified within the Totiviridae are
comprised of a single-segmented double-stranded RNA (dsRNA)
genome that encodes only a capsid protein and an RNA-dependent
RNA polymerase (RDRP) (8, 9). Leishmaniavirus is most frequently
found in New World parasite species in the subgenus Viannia [as
Leishmania RNA virus 1 (LRV1)], such as Leishmania braziliensis
(Lbr) and Leishmania guyanensis (Lgy), which cause both cutaneous
and mucocutaneous disease (6), and is found sporadically in Old
World subgenus Leishmania species [as Leishmania RNA virus 2
(LRV2)] (10, 11). Mice infected with LRV1-bearing strains of
L. guyanensis exhibit greater footpad swelling and higher parasite
numbers than mice infected with LRV1− L. guyanensis (7). Similarly,
macrophages infected in vitro with LRV1+ L. guyanensis or LRV2+
Leishmania aethiopica release higher levels of cytokines, which are
dependent on Toll-like receptor 3 (7, 10). Recently, methods for
systematically eliminating LRV1 by RNA interference have been
developed, enabling the generation of isogenic LRV1− lines and
allowing the extension of the LRV1-dependent virulence paradigm
to L. braziliensis (12).
A key question is the relevancy of the studies carried out in
murine models to human disease. For L. guyanensis, patients
infected with LRV1+ strains show an increased severity of cu-
taneous disease (13). In humans, L. braziliensis is associated with
cutaneous leishmaniasis, as well as the larger share of the more
debilitating mucocutaneous leishmaniasis (MCL). Thus far there
are no data available in humans permitting tests of the associa-
tion of LRV1 with L. braziliensis parasite burden nor the severity
of cutaneous leishmaniasis (CL), which can show a range of
presentations (14, 15). In lieu of such information, studies have
focused on the association of LRV1 with MCL vs. CL, which is
thought to reflect primarily immunopathology rather than par-
asite numbers (2, 6, 14–16). Although in some studies LRV1 was
not correlated with MCL clinical manifestations (17, 18), in
others there was a strong association (6, 19, 20). The basis for
these discrepancies is of considerable interest, hypotheses for
which include other parasite or host factors known to play a
significant role in the development of MCL (13, 21, 22), or
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microbial sources including the microbiota or coinfections (23).
Recent studies show that the presence of LRV1 in clinical iso-
lates of L. braziliensis and L. guyanensis correlates with drug-treat-
ment failure (17, 20), phenomena that could readily be explained by
the increased parasite numbers or altered host responses predicted
from animal models (7, 13, 24). Thus, current data support a role
for LRV1 in increasing disease severity in human leishmaniasis (13);
this suggests that therapies targeting LRV1 specifically could be
applied toward amelioration of disease pathology. As one approach,
murine vaccination using the LRV1 capsid results in significant
protection against LRV1+ L. guyanensis (25).
Here we describe a complementary approach, targeting LRV1
directly using small-molecule inhibitors. Although effective anti-
virals are available for many viral targets including retroviruses,
DNA viruses, and single-strand RNA (ssRNA) viruses (26), little
effort has gone into agents acting against dsRNA viruses (27).
These comprise at least 10 viral families (Birnaviridae, Boty-
birndaviridae, Chrysoviridae, Cystoviridae, Megabirnavirdae,
Partitiviridae, Picobirnaviridae, Quadriviridae, Reoviridae, and
Totiviridae), infecting a wide array of hosts, including fungi, plants,
and animals (28). Some constitute important agricultural pathogens
and rotaviruses (Reoviridae) cause serious human disease. For
protozoan viruses, their role in the exacerbation of human disease is
only now beginning to be appreciated (6, 29). Because viral ele-
ments are critical factors acting to exacerbate the disease where
studied, candidate anti-LRV1 agents should be viewed as “anti-
pathogenicity” treatments rather than sterilizing cures (30), which
could be used alone or more likely in combination with existing
antileishmanial agents in the treatment of ongoing infection.
As a starting point, we focused on nucleoside analogs, a class
that includes many widely used and effective antivirals (Table
S1) (26). Following uptake and activation to the triphosphate
form, these analogs primarily target viral replication, with dif-
ferent classes acting preferentially against viral DNA or RNA
polymerases (RDRP) or reverse transcriptases, as well as cellular
metabolism. A second rationale was that Leishmania are purine
auxotrophs, with highly active and multiply redundant pathways
for uptake and activation of nucleobases and nucleosides (31).
Indeed, a great deal of prior effort has been devoted to the de-
velopment of antileishmanial purine analogs; however, whereas
the nucleobase allopurinol is commonly used as a veterinary agent,
it has proven more difficult to find agents of sufficient potency and
selectivity against Leishmania to be used widely against human
leishmaniasis (32). We reasoned that the highly divergent prop-
erties of Totiviridae RDRPs, relative to the polymerases of both
the Leishmania and mammalian hosts (as well as other viral
RDRPs), could prove fertile grounds for antiviral discovery, es-
pecially when coupled with potentiation by the parasite’s powerful
nucleoside/base salvage pathways.
Results
Measurement of LRV1 Levels by Capsid Flow Cytometry. Because
LRV1 (like most Totiviridae) is not shed from the cell (33, 34),
we developed a flow cytometric assay to measure intracellular
LRV1 capsid levels on a per cell basis. To detect LRV1 we used
binding to a rabbit anti-LgyLRV1 capsid antiserum (35) followed
by detection with Alexa Fluor488-conjugated goat anti-rabbit
IgG. We found that fixation with 2% (wt/vol) paraformaldehyde
followed by permeabilization with Triton X-100 yielded a clear
LRV1-dependent profile (Fig. 1A). Titration of the anticapsid
antiserum showed that dilutions around 1:16,000 gave a strong
signal with excellent selectivity between LgyLRV1+ and LRV1−
(Fig. 1B), with little background staining evident in immunofluo-
rescence microscopy. Under these conditions and as seen in pre-
vious immunofluorescence studies (36), LgyLRV1+ showed a
strong, homogeneous LRV1 distribution (Fig. 1A). We attempted
similar studies with anti-dsRNA antibodies (36), but were unable
to identify fixation conditions that gave similarly clear discrimi-
nation between LgyLRV1+ and LRV1− by flow cytometry.
Inhibition Tests. We acquired a collection of 81 compounds, pri-
marily nucleoside or nucleobase analogs, including ones shown
previously to be active against diverse viruses, tumor cells, or
Leishmania (Fig. S1 and Tables S1 and S2). These compounds
were examined for their ability to inhibit the growth of LgyLRV1+
and virus levels by LRV1 capsid flow cytometry. LgyLRV1− par-
asites grew similarly to LgyLRV1+ and were used as virus-negative
controls. These data revealed three patterns (Fig. 2). For most
compounds, LRV1 capsid levels were not significantly affected,
within a factor of ∼3 (Fig. 2, black or red dots within large dashed
gray and red circles, Fig. S2, and Table S2). All nucleobase analogs
fell within this group, as did foscarnet (a structure analog of py-
rophosphate). Within this group, a subset showed more than
10-fold inhibition of L. guyanensis growth (Fig. 2, red dashed circle
and black dots above; Fig. S3 A and B; and Table S2), including
known antileishmanials, such as allopurinol, mycophenolic acid,
and 4-aminopyrazolopyrimidine (APP). Several additional com-
pounds showed leishmanial inhibition at the concentration tested
(Fig. 2, Fig. S2B, and Table S2); however, these were deprioritized
for various reasons, including known mammalian cell toxicity. In
the initial screens several compounds showed modest elevation of
Fig. 1. Anti-LRV1 capsid flow cytometry. LgyLRV1+ and LgyLRV1− parasites
were fixed and permeabilized followed by staining with increasing dilutions of
anticapsid antibody and fluoresceinated secondary antibody. (A) Profiles
obtained with LgyLRV1+ (solid line) and LgyLRV1− (filled) after selection for
single cells. A representative experiment is shown, performed at a dilution of
1:16,000; subsequent studies were performed using a dilution of 1:20,000
(n > 11). (B) Mean fluorescence of LgyLRV1+ (■) and LgyLRV1− (□) for each
antibody dilution. The ratio of LRV1+/LRV1− staining (●) is plotted as a solid line.
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LRV1, often accompanied by growth inhibition (Fig. 2, Fig. S2A,
and Table S2). However, this effect was not always reproducible
and was not pursued further.
Two compounds strongly reduced LRV1 capsid levels with
minimal impact on parasite growth (Fig. 2, green circle, Fig.
S1 and Table S2). Both 2′-C-methyladenosine (2CMA) and
7-deaza-2′-C-methyladenosine (7d2CMA) resulted in 12-fold re-
ductions in LRV1 capsid levels, showing 30% and 90% inhibition
of parasite density, respectively, when tested at 100 μM. Both had
previously been shown to inhibit the hepatitis C virus (HCV)
RDRP following activation (37, 38). In contrast, 2′-C-methyl-
cytidine or guanosine had little effect on LRV1 levels orL. guyanensis
growth (Fig. 2, blue dots). Compounds bearing a variety of other 2′
modifications (alone or in combination, with various bases) showed
little effect on LRV1. These included sofosbuvir and mericitabine
(related to 2′-C-methyl-2′-F uridine or cytidine, respectively), both
of which show strong activity against HCV (39, 40), or NITD008,
which shows good activity against flaviviruses (41). These data
suggest a strong preference for both the nature of the 2′-C sub-
stitution, as well as adenine as the base. Note that these data cannot
discriminate between effects arising from direct inhibition of RDRP
or other viral processes, nor drug metabolism (phosphorylation or
resistance to nucleoside hydrolases).
Previously, a Leishmania cysteine proteinase activity was im-
plicated in the cleavage of the LRV1 capsid–RDRP fusion
protein, potentially important for LRV1 biogenesis (42). How-
ever, no effects on L. guyanensis growth and only minimal effects
on LRV1 capsid levels were observed with three cysteine pro-
teinase inhibitors tested (E64, E64d, and CA-074) (Table S2),
relative to the effects of 2CMA or 7d2CMA.
2CMA Preferentially Inhibits LRV1 Replication. Titrations were per-
formed to quantitate the potency of 2CMA and 7d2CMA against
L. guyanensis growth and LRV1, measuring the relative cellular
growth rate to better assess fitness effects. For 2CMA, the EC50
was estimated to be ∼3 μM for LRV1 capsid inhibition, versus
>100 μM for parasite growth (Fig. 3A), at least 30-fold selective.
To assess the effects on replication of the dsRNA LRV1 genome
directly, we used quantitative anti-dsRNA slot blots (Fig. 3A)
(36), which showed an EC50 of ∼1 μM, slightly less than
seen with capsid inhibition and consistent with the anticipated
targeting of the RDRP. With 7d2CMA, an EC50 of ∼5 μM was
seen against LRV1 capsid expression, versus ∼ >100 μM for
L. guyanensis growth, again with about >20-fold selectivity
(Fig. 3B). Several studies were carried out with L. braziliensis
strains bearing LRV1 (12). The 2CMA EC50 for LbrLRV1 was
similar to that seen with LgyLRV1 (∼3 μM); however, parasites
were somewhat more susceptible to growth in inhibition (EC50
50–100 μM). Because the available quantities of 7d2CMA were lim-
iting and both compounds were similarly selective for L. guyanensis,
we focused thereafter on 2CMA.
Inhibition of 2CMA LRV1 Is Unaffected by Exogenous Adenine, nor Is
Synergy Seen with Antileishmanial Nucleobases. We asked whether
the 2CMA potency was affected by the presence of exogenous
adenine, present at about 5–33 μM in the yeast extract compo-
nent of Schneider’s medium (43). The addition of adenine up to
400 μM had no impact on LRV1 inhibition by 100 μM 2CMA,
nor did it alter LRV1 levels in LgyLRV1+ (Fig. S3C). APP
showed similar inhibition of L. guyanensis growth and LRV1
levels, whereas at the highest concentration tested, allopurinol
inhibited L. guyanensis growth or LRV1 capsid levels by 30 or
60%, respectively (Fig. S3A). We then explored potential in-
teractions between 2CMA and antileishmanial nucleobases.
However, no change in the EC50 for 2CMA inhibition of
L. guyanensis growth or LRV1 capsid synthesis was seen with
increasing concentrations of allopurinol (∼3 μM) (Fig. S3D).
Fig. 2. Antiviral inhibition of L. guyanensis growth vs. LRV1 inhibition. The
figure shows data from Table S2 plotted; LRV1 capsid levels (y axis) vs.
L. guyanensis growth (x axis). The large dashed gray circle marks compounds
(black dots) showing little effect on LRV1 or L. guyanensis, the red circle
marks compounds preferentially inhibiting L. guyanensis growth, and the
green circle marks compounds preferentially inhibiting LRV1; blue dots de-
pict 2′C substituted nucleosides without anti-LRV1 activity. LgyLRV1+ and
LgyLRV1− controls are shown in brown. Abbreviations for compounds dis-
cussed further in the text can be found in Table S1.
Fig. 3. 2CMA and 7d2CMA inhibition of L. guyanensis growth and LRV1 capsid
or RNA levels. The figure shows the rate of growth or LRV1 capsid levels (y axis)
as a function of drug concentration. (A) 2CMA; (B) 7d2CMA. Growth rate (●,
solid line) and normalized LRV1 capsid (□, dashed line) or RNA (Δ, dashed line)
are shown. The results of one representative experiment are shown for 2CMA
(n = 2 for RNA and capsid) and a single experiment for 7d2CMA.
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LRV1 Inhibition Is Independent of Leishmania Growth Inhibition.
Agents inducing stress or growth arrest have been used to cure
fungal Totiviridae, with cycloheximide (CHX) used often (44, 45).
Growth of L. guyanensis at 10 or 100 nM CHX resulted in an
increase in population doubling time, from ∼7.7 h to 11.2 or
44.7 h, respectively, without significant cell death as evidenced by
resumption of WT growth following CHX removal (Fig. 4A).
Despite the strong effects on growth, LRV1 capsid levels were
unaffected, nor was the emergence of a “LRV1−” parasite pop-
ulation seen at any CHX concentration (Figs. 4 B and C). Similar
results were obtained with clotrimazole, which inhibits Leishmania
growth through inhibition of sterol synthesis (Fig. 4D). Finally, no
correlation was seen between LRV1 levels and growth rate in our
test compound screening (Fig. 2 and Fig. S2) or exposure to
hygromycin B (46). Thus, inhibition of Leishmania growth alone
does not alter LRV1 levels.
Viral Loss Occurs by Random Dilution. The availability of an in-
hibitor with strong selectivity for LRV1 over parasite growth
provided an opportunity to test the assumption that cytosolic
Totiviruses are passed randomly to daughter cells during mitosis
(34, 47). For maximal LRV1 inhibition, parasites were in-
oculated into 100 μM 2CMA, which increased the population
doubling time from 6.4 to 8.5 h (Fig. 3). The average LRV1
levels immediately declined, with capsid and RNA levels falling
in parallel (Fig. 5 A and B). Importantly, when plotted as a
function of number of cell divisions, loss of LRV1 capsid and
RNA followed a first-order linear relationship, with a 50% loss
at every doubling (Fig. 5 A and B). When visualized at the
population level by flow cytometry, LRV1 capsid levels per cell
declined homogeneously at every time point tested until only
background staining was evident by six cell doublings (Fig. 5C).
Both of these observations closely match the expectation for the
random distribution of LRV1 particles to daughter cells during
mitosis and successive cell divisions.
2CMA Induces LRV1− Populations. To explore the loss of LRV1
further, we performed a series of “washout” experiments,
growing LgyLRV1+ in 100 μM 2CMA for one, three, four, or six
cell doublings followed by transfer to drug-free media. After one
doubling, a time when LRV1 levels had only decreased twofold,
LRV1 capsid levels rapidly returned to WT levels and distribution.
In contrast, when 2CMA was maintained for three or four cell
doublings, resulting in a homogeneous population showing on
average 8- or 16-fold less LRV1 capsid expression, the washout
lines now showed two distinct populations (Fig. 5 C and D). One
population expressed LRV1 at levels similar to control LgyLRV1+,
whereas the other resembled LgyLRV1− (Fig. 5D, Top and
Middle). Parasites with LgyLRV1+ capsid levels were the majority
(55%) in the three-doubling washout population, whereas these
had declined to 36% percent in the four-doubling washout pop-
ulation (Fig. 5D). The LgyLRV1− population increased from 31 to
50% of the total cell population during this time. Finally, after six
cell doublings of growth with 2CMA, the LRV1 capsid profile was
indistinguishable from that of the LgyLRV1− and the six-doubling
washout population revealed only parasites maintaining the
LgyLRV1− capsid-staining profile (Fig. 5D). This population
was maintained for at least six passages (∼40 cell doublings)
without return of any demonstrable LRV1+ parasites.
Several conclusions emerge from these studies: first, the ef-
fective LRV1 copy number per cell must be relatively low, as
otherwise an LRV1− population could not emerge after only
three to six cell doublings (Fig. 5), roughly corresponding to copy
numbers of 8–64 (23 − 26) and consistent with fraction of LRV1−
cells emerging in the washouts (Fig. 5D). LgyLRV1 copy number
was previously estimated as 24–100 by competitive PCR assay
(48). To assess LRV1 copy number independently in the clonal
LgyLRV1+ line studied here, we isolated total RNA quantita-
tively from a known number of cells, and estimated LRV1 copy
number by quantitative RT-PCR (qRT-PCR), using a standard
curve established from a cloned LRV1 genome (Methods). This
process yielded an estimated average LRV1 copy number of
15 ± 0.9 per cell (n = 3), consistent with range estimated from
the rate of drug-induced loss above.
Second, after washout, 2CMA-treated parasites, which origi-
nally showed homogeneous low levels of LRV1, now reverted to
biphasic populations showing WT or “negative” LRV1 levels.
The recovery of the WT-like population suggests that there may
be a “set point” for LRV1 levels. Because only populations but
not clones were studied, we cannot be sure that this occurred
intracellularly; however, the rapidity with which LRV1 levels
rebounded suggests this may be more likely.
Rapid Recovery of Matched Clonal WT and LRV1-Cured Lines. Our
findings suggested that it should be relatively easy to recover
LRV1− clonal lines from the 2CMA-treated population. How-
ever, we were concerned that despite small effects on growth, the
relatively high concentration of 2CMA used above could itself
have unwanted selective effects on L. guyanensis. Support for this
concern arose when in pilot studies, several clonal lines obtained
after growth in 100 μM 2CMA lacked LRV1 but showed de-
creased growth inhibition by 2CMA. Thus, we repeated the
LRV1 cure using 10 μM 2CMA, a concentration showing less of
an effect on parasite growth but retaining strong inhibition of
LRV1 levels (Fig. 3). Again, loss of LRV1 proceeded homoge-
neously (Fig. 6A). When clonal lines were recovered directly by
plating from this population, very few were LRV1− (1 of 30).
However, if the population was allowed to grow in the absence of
2CMA for another ∼six cell doublings (washout), a bimodal
population for LRV1 capsid levels emerged, as seen previously.
Analysis of 12 clonal lines obtained by direct plating from this
washout population showed that six exhibited LRV1 capsid
levels/profiles identical to the LgyLRV1− control, whereas two
showed profiles identical to the LgyLRV1+ parent (representa-
tives shown in Fig. 6B). Interestingly, four lines showed more
complex profiles, with populations showing range of intensities
Fig. 4. LRV1 levels are unaffected by agents inhibiting L. guyanensis
growth. (A) LgyLRV1+ was treated with 10 nM CHX (□, dashed line), 100 nM
CHX (○, dashed line), or no treatment (■, solid line). After 72 h, cells treated
with 100 nM CHX were placed into fresh media (●, dashed line). (B) Profiles
obtained by LRV1 flow cytometry after 48 h growth for WT (shaded) or cells
treated with 100 μM CHX (solid line), or 10 μM CHX (dashed line). (C) Plot of
growth rate of LgyLRV1+ (●) or LRV1 capsid levels (□, dashed line) after 48-h
propagation in increasing concentrations of CHX. (D) As in C but for clo-
trimazole (CTZ). A representative experiment is shown (n = 3).
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spanning those from LRV1− to LRV1+ controls (representative
shown in Fig. 6B). These complex lines were not studied further.
The set-point hypothesis predicts that upon further growth, those
lines would ultimately revert to bimodal populations.
We chose two LRV1+ and LRV1-cured lines that had expe-
rienced identical 2CMA treatment and culture manipulations.
Growth tests confirmed these were not resistant to 2CMA, and
RT-PCR and Western blot tests confirmed the presence or ab-
sence of LRV1 (Fig. 6 C and D). These clones thus constituted
matched WT and LRV1-cured lines appropriate for subsequent
studies of LRV1 effects.
LRV1 Correlates with Increased Cytokine Secretion and Mouse Infectivity.
With matched 2CMA-treated LRV1+ and LRV1− (cured) lines, we
asked whether LRV1 was correlated with elevated pathology and
hyperinflammatory responses, as expected (7, 12). Infections were
performed with bone marrow-derived macrophages (BMM) in vitro,
followed by assays for secretion of two characteristic LRV1-dependent
cytokine reporters, IL-6 and TNF-α. Cytokine secretion induced by
the LRV1+/2CMA-treated lines was comparable to that of the pa-
rental LgyLRV1+ line, whereas cytokine secretion induced by the
2CMA cured lines was considerably less, and comparable to that of
the LgyLRV1− control (Fig. 7 A and B).
Infections of susceptible BALB/c mice were performed fol-
lowed by measurement of pathology (footpad swelling) and
bioluminescent imaging of parasite numbers. A strong LRV1-
dependency for both pathology and parasite abundance was
observed in comparisons of the matched 2CMA-treated LRV1+
vs. LRV1− (cured) lines (Fig. 7 C and D). Importantly, the re-
sponse to the 2CMA-treated LRV1+ lines closely matches that
to the control parental LgyLRV1+ line and, similarly, the re-
sponse to the 2CMA-treated LRV1− line closely matches that to
the LgyLRV1− control (Fig. 7 C and D), both of which were
studied previously (7).
Discussion
In this study, we report the identification of compounds specif-
ically targeting the LRV1 dsRNA virus of L. guyanensis and
L. braziliensis, two representatives of the Totiviridae. Our find-
ings have relevance for the specific therapeutic inhibition of
Leishmaniavirus, basic studies of viruses within the Totiviridae,
the development of antivirals directed against dsRNA viruses
generally, and the development of new tools for assessing the role
of LRV1 in elevating Leishmania pathogenicity.
To facilitate the search for LRV1 inhibitors, we first de-
veloped a capsid flow cytometry assay to rapidly monitor LRV1
capsid levels (Fig. 1). This assay can be performed in only a few
hours, and although these studies used it in a relatively low
throughput manner, it should be scalable for higher throughput.
The results were confirmed by anticapsid or anti-dsRNA West-
ern or slot blotting, or quantitative RT-PCR (Fig. 6 C and D).
Additionally, this assay provides useful information about the
cellular heterogeneity of LRV1 levels not readily achievable by
other methods, which informed studies probing the inheritance
of LRV1 as well as in the generation of LRV1− lines.
We focused on known antivirals for several reasons: first, de-
spite significant advances in targeting many retroviruses, DNA
viruses, or ssRNA viruses, very little effort or progress has been
devoted on inhibition of dsRNA viruses. Thus, there seemed a
reasonable potential for “repurposing” known antivirals against
the dsRNA Leishmaniavirus. Moreover, because many antivirals
are nucleoside analogs and that Leishmania is a purine auxotroph
(31), the pharmacokinetics of drug uptake and metabolism could
well favor the efficacy of such compounds against Leishmaniavirus.
As a collateral benefit, these studies had the potential to uncover
new lead inhibitors against Leishmania itself, as auxotrophy has
prompted many investigators to target purine metabolism for
antileishmanial therapy. Several new compounds not previously
reported to inhibit Leishmania were identified (Fig. 2 and Tables
S1 and S2), but were not pursued further here.
We identified two compounds that showed preferential inhibition
of LRV1, 2CMA, or 72CMA (Fig. 3 and Fig. S1). The two active
compounds were effective in the micromolar range, with >20-fold
selectivity for LRV1 versus L. guyanensis growth inhibition and
were also active against LbrLRV1, albeit with somewhat less se-
lectivity over growth. The EC50 measured using dsRNA or capsid
levels were similar, with that of the dsRNA being somewhat less,
consistent with the anticipated mode of action targeting the RDRP
and genome replication. Both compounds have demonstrated
Fig. 5. Kinetics of and cellular distribution of LRV1 loss after treatment with 100 μM 2CMA. (A and B) LgyLRV1+ was inoculated into media without (●) or
with (□, Δ) 100 μM 2CMA, and growth and LRV1 capsid (□, dashed line) and RNA levels (Δ, dashed line) measured by capsid flow cytometry (A) or qRT-PCR (B).
For A, results at each time are shown normalized to LRV1+ and LRV1− control levels using the formula log2 (2CMA treated − LRV1−)/(LRV1+ − LRV1−). For B,
the log2 ddCT values are shown. A theoretical 1:2 dilutional loss is shown (thin gray line); error bars represent ±1 SD. (C) LRV1 capsid flow cytometry of control
parasites (Top) and populations grown for one, three, four, or six cell doublings in 100 μM 2CMA. (D) LRV1 capsid flow cytometry of parasites grown for three,
four, or six doublings in 100 μM 2CMA, and then grown for an additional six cell doublings in drug-free media (washouts). Thick and thin gray dashed lines
represent LgyLRV1+ and LgyLRV1−, respectively.
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activity against HCV, where they target the viral RDRP by chain
termination (37, 38, 49). By molecular modeling of the L. guya-
nensis LRV1 RDRP domain against other RDRPs, such as HCV,
we were able to generate a view of the active site including residues
putatively binding to the nucleotide substrates (Fig. S4). Notably,
these included sites homologous to those mutated in HCV nu-
cleoside analog-resistant lines (50). This finding supports our
working hypothesis that both anti-LRV1 compounds are activated
to triphosphates, where they act to inhibit RDRP activity. These
compounds represent the only inhibitors known to act against
any member of the Totiviridae, and indeed some of the few
candidates described inhibiting dsRNA viruses generally.
Common features of the two selective anti-LRV1 compounds
include the 2′-C methyl and the adenine base moieties, although 2′
C-methyl G and C were inactive against both Leishmania and
LRV1. A similar pattern was observed for dengue virus RDRP
inhibitors, where only adenosine analogs demonstrated antiviral
activity (51). Following uptake, in Leishmania most purine nucleo-
sides are metabolized to nucleobases, the major exception being
adenosine, which is phosphorylated directly by adenosine kinase
(31). This finding could contribute to the superiority of 2CMA
analogs. However, all other 2′C-modified analogs tested failed to
inhibit LRV1 or Leishmania, including ones bearing adenine or
related moieties as the nucleobase (Fig. 2 and Tables S1 and S2).
Other factors may include differential ability to be phosphorylated,
often the rate-limiting step for antiviral nucleoside activation (52, 53),
or susceptibility to nucleoside hydrolases or phosphorylases, which
Leishmania possess in abundance (31), and affinity of the phos-
phorylated analog with the LRV1 RDRP itself. Additional studies
will be required to assess the contributions of each of these factors to
anti-LRV1 activity and the design of more potent inhibitors.
Anti-LRV1 Agents as a Tool for Studying Leishmaniavirus Replication
and Biology. The LRV1 selectivity of 2CMA and 7d2CMA pro-
vided the foundation for several studies probing LRV1 biology.
Under 2CMA inhibition, a first-order kinetic loss of LRV1 was
observed, (measured by either capsid or dsRNA genome levels),
with a homogeneous 50% loss at every cell doubling (Fig. 5 A
and B). This finding fits exactly the prediction assumed by a
random-inheritance model of LRV1 particles during mitosis.
Although widely assumed for the inheritance of most persistent
dsRNA viral infections, these findings now provide direct evi-
dence of random segregation. These data also provide a mech-
anistic explanation for the failure to identify compounds inhibiting
both LRV1 and L. guyanensis in our screen, because without
continued parasite growth LRV1 cannot be lost by dilution, and
indeed may increase somewhat (Fig. 2).
Ultimately, LRV1 levels declined to levels approaching those
of LRV-free parasites within three to six cell doublings following
2CMA treatment (Fig. 5). This finding implies the viral copy
number was relatively low, less than 8–64 (23–6), significantly less
than previous estimates of 120 for LgyLRV1 and often many
thousands for other Totiviridae (34, 48). However, quantitative
analysis of cellular LRV1 and total RNA led to an estimate of
about 15, consistent with estimates of LRV1 abundance from
recent whole-genome RNA sequencing by our group. If this
unexpectedly low value for LRV1 copy number applies generally
to LRV1s in other Leishmania strains or species, it could provide
Fig. 6. Generation of matched LRV1+and cured lines after limited 10 μM
2CMA treatment. (A) Workflow for treatment of parasites with 10 μM 2CMA
before isolation of clonal lines. First drug treatment for 6.4 cell doublings
generates a population containing low average LRV1 levels, then the
washout for 6 cell doublings allows resolution into fully negative or LRV1+
lines. (B) Representative LRV1 capsid profiles for a cured line (L. guyanensis
clone 10-5), a WT-like line (L. guyanensis clone 10-10), and a mixed profile
line (L. guyanensis clone 10-1; for clarity the leading “10” is omitted from
the figures). (C) RT-PCR tests confirming presence or absence of LRV1 in
treated lines. RT+, reverse transcription performed before PCR; RT−, no re-
verse transcription step. M, 1 kb+ ladder, Invitrogen. The expected LRV1
capsid and β-tubulin amplicons of 496 and ∼450 nt were found. (D) Western
blotting with anti-LgyLRV1 capsid antisera confirms absence of LRV1 in
cured lines L. guyanensis 10-5 and 10-6. M, molecular weight marker. The
arrowhead marks the position of the 95-kDa LRV1 capsid band.
Fig. 7. Matched 2CMA-treated LRV1+ and LRV1− cured lines recapitulate
LRV1-dependent virulence. (A and B) Cytokine secretion by BMM infected 24 h
after infection with L. guyanensis lines or treatment with poly I:C (2 μg/mL),
M, media. (A) TNF-α; (B) IL-6. The figure shown is representative of three
experiments, each done in triplicate; error bars represent ± SD. (C and D)
Infections of matched 10 μM 2CMA treated LgyLRV1+ and LgyLRV1−. Para-
site numbers (luminescence from luciferase reporter) (C) or footpad swelling
(D) was measured at the peak of the infection (28 d). Each bar represents
pooled data from eight mice total, four for each Lgy line used. LRV1+ (clones
10-9 and 10-10) and LRV1− (clones 10-5 and 10-6) lines are shown; error bars
represent ± SD. Data for control parasites are replotted from Ives et al. (7).
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a new perspective on the observation that thus far, no images of
LRV1 in situ by electron microscopy appear in the literature.
The rapid decline of LRV1 following 2CMA treatment sug-
gested that it would be relatively easy to recover LRV1-free
clonal lines. Following washout of 2CMA after three to six cell
doublings and a brief period of growth without drug, cultures
manifested two distinct parasite populations by capsid flow
cytometry: one similar to LgyLRV1+ and a second similar to
LgyLRV1− (Figs. 5 and 6). The fraction of LgyLRV1− parasites
grew progressively with increasing 2CMA treatment, reaching
levels approaching 100%. To recover parasites suited for studies
focusing on the biological properties of LRV1− parasites, we
adopted a protocol in which parasites were treated for only a
brief period with 10 μM 2CMA, a concentration showing little
effect on parasite growth but relatively high inhibition of LRV1
(Fig. 3), followed by brief passaging and then plating on drug-
free media. Importantly, this procedure allowed the recovery of
both LRV1+ and LRV1− matched clonal lines, which had ex-
perienced identical treatment, thereby facilitating comparisons
probing LRV1 effects (below). Interestingly, in all of these
studies the LRV1 levels in washout lines showed a strong ten-
dency to recover from the low levels seen in drug to those
comparable to LRV1+ controls (Fig. 5). These findings suggest
that the LRV1 copy number is maintained at a specific set point,
perhaps through a balance between replication and the RNAi
pathway (12, 54). Previous studies examining LRV1 transcripts
during growth phase also concluded that LRV1 copy number is
regulated (48).
For other fungal dsRNA viruses, treatments engendering cell
stress or growth inhibition have been used to generate virus-free
lines at significant frequencies, one common example being the
use of CHX to cure the yeast L-A virus (44). Although in one
prior study LRV1 cure was obtained during a series of trans-
fection and hygromycin selection steps, this appears to have been
successful only once, and our laboratories have been unable to
repeat this (12, 46). Here we were unable to show any correlation
between LRV1 loss and drug-induced stress or growth inhibition
with CHX, the ergosterol synthesis inhibitor clotrimazole, or
within the large panel of test compounds (Figs. 2 and 4, Fig. S2,
and Tables S1 and S2). Thus, LRV1 appears to be relatively
stable to growth inhibitory stresses. However, given its relatively
low cellular copy number (<20), on a strictly probabilistic basis
LRV1− variants might occur at a low frequency, which occa-
sionally may emerge or be recovered by methods more sensitive
than used here.
Antiviral Cures and the Generation of Isogenic LRV1− Lines for the Study of
LRV1-Dependent Virulence. Treatment with 2CMA enables the con-
trolled and reproducible generation of matched LRV1+ and LRV1-
cured lines without difficulty. In vivo, 2CMA-cured LRV1− parasites
showed less pathology and lower parasite numbers and induced less
cytokine secretion than LRV1+ parasites, comparable to the single
spontaneous LRV1− lines described previously (Fig. 7). Thus, our
LRV1 toolkit now includes two independent, reproducible, and ef-
ficient methods for generating isogenic LRV1− lines, which will fa-
cilitate tests probing the biology of LRV1-dependent pathogenicity in
diverse parasite backgrounds. Depending on the relative selectivity of
the antivirals and the presence of an RNAi pathway, one method
may be superior for a given Leishmania species or strain.
The Potential for Antitotiviral Therapy in the Treatment of dsRNA-
Bearing Parasites and Disease. There are now ample data sug-
gesting that LRV1 contributes to the severity in human leish-
maniasis (6, 13, 17, 19, 20, 55), suggesting that anti-LRV1
inhibitors could be clinically useful, alone or in conjunction with
existing antileishmanials. Unfortunately, pharmacokinetic stud-
ies of the two compounds studied here in mammals suggest that
neither of these are good candidates for testing of this hypothesis
just yet, as the concentration needed for LRV1 elimination (10 μM)
is above the maximum achievable serum concentration in various
mammalian models, typically less than 1 μM (38, 49, 56). Thus,
future efforts must focus on the development of compounds with
higher potency targeting LRV1, without significant human host
toxicity. For therapeutic purposes a compound simultaneously tar-
geting both would likely be superior. However, because Leishmania
growth is required for LRV1 to be lost by progressive dilution
(Fig. 5), a screening method different from that used here will be
required to detect such agents. Dilutional loss following anti-LRV1
inhibitor treatment in vitro predicts that very low levels of LRV1
could persist after treatment in vivo, whether measured on a total or
per cell basis (Fig. 5). Importantly, previous data show that below a
certain threshold, parasites bearing low LRV1 levels are controlled
as effectively as LRV1− lines (7).
Our studies also raise the possibility of treating other diseases
caused by protozoans bearing dsRNA viruses, which show endoge-
nous virus-dependent pathogenicity, including Totiviridae present
within Trichomonas vaginalis (Trichomonasvirus), Giardia lamblia
(Giardiavirus), or Eimeria (Eimeravirus) (34, 57), and Partitiviridae
within Cryptosporidium parvum (Cryspovirus) (58, 59). Potentially,
agents targeting these putative pathogenicity factor viruses could
prove similarly valuable for laboratory studies of these viruses as well.
Methods
Parasites and Growth Media. Most studies were performed using luciferase-
expressing transfectants of L. guyanensis (MHOM/BR/78/M4147) described
previously [LRV1+ LgyM4147/SSU:IR2SAT-LUC(b)c3 and LRV− LgyM4147/
pX63HYG/SSU:IR2SAT-LUC(b)c4] (54); these lines are termed LgyLRV1+ and
LgyLRV1−, respectively. Two strains of LRV1+ L. braziliensis were examined:
LEM2780 (MHOM/BO/90/CS) and LEM3874 (MHOM/BO/99/IMT252 no. 3) (12).
Parasites were grown in Schneider’s media (Sigma) prepared according to
the supplier’s instructions with pH adjusted to 6.5 and supplemented with
0.76 mM hemin, 2 μg/mL biopterin, 50 U/mL penicillin, 50 μg/mL strepto-
mycin, and 10% (vol/vol) heat-inactivated FBS. Cell concentrations were
determined using a Coulter Counter (Becton Dickinson).
Drug-Inhibition Tests. Compoundswere purchased or obtained as summarized
in Table S1, and the structures of the two most active anti-LRV1 compounds
are shown in Fig. S1. Stock solutions were prepared as recommended by the
source, typically in DMSO at 50 mM, and tested against parasites at 100 μM
or the maximum concentration permitted by drug solubility (Table S2).
Parasites were inoculated at 2 × 105 cells/mL into Schneider’s media lacking
supplemental adenine. Growth was evaluated after 2 d, before the controls
reached stationary phase growth, at which time parasite numbers had in-
creased nearly 100-fold. Experiments were performed in sets of 10 test
compounds, along with LRV1+ and negative controls; the agreement among
independent experiments among the controls was excellent, and the results
are shown averaged together across all experiments (Table S2).
LRV1 Capsid Flow Cytometry. For capsid flow cytometry, 107 cells were fixed at
room temperature using 2% (wt/vol) paraformaldehyde (Thermo Fisher) in
PBS for 2 min. They were then incubated in blocking buffer [10% (vol/vol)
normal goat serum (Vector Laboratories) and 0.2% Triton X-100 in PBS] for
30 min at room temperature. Anti-LgyLRV1 capsid antibody (35) was added
(1:20,000 dilution) and incubated at room temperature for 1 h. After two
washes with PBS, cells were resuspended in in 200 μL PBS with Alexa
Fluor488-labeled goat anti-rabbit IgG (Alexafluor, Invitrogen; 1:1,000; or
Thermo Fisher; 1:2,000 dilution), and incubated 1 h at room temperature.
After two additional washes with PBS, cells were subjected to flow cytom-
etry, gating for single cells using forward and side scatter and the data
analyzed using CellQuest software (BD Bioscience).
RNA Purification, cDNA Preparation, and qRT-PCR. For RNA purification, 107
cells were resuspended in 350 μL TRIzol Reagent and RNA was extracted
using the Direct-zol RNA purification kit according to protocol (Zymo Re-
search). RNA was then treated with DNase I (Ambion) for 1 h at 37 °C and
repurified using RCC-5 column purification (Zymo Research). cDNA was
prepared using SuperScript III (Invitrogen) and random priming according to
protocol. RNA denaturation occurred at 65 °C for 5 min. RT-PCR tests were
performed using LRV1-specific primers (SMB4647 5′-TBRTWGCRCACAGTGAY-
GAAGG and SMB4648 5′CWACCCARWACCABGGBGCCAT) or β-tubulin mRNA
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(SMB5023 5′-AACGCTATATAAGTATCAGTTTCTGTACTTTA and SMB2110
5′-GACAGATCTCATCAAGCACGGAGTCGATCAGC). qRT-PCR was performed as
previously described (36), with a 123-bp fragment of LRV1 capsid mRNA am-
plified with primers SMB5335 (5′-CTGACTGGACGGGGGGTAAT) and SMB5336
(5′-CAAAACACTCCCTTACGC), and a 100-bp fragment of KMP-11 (a Leishmania
housekeeping gene) with primers SMB5548 (5′-GCCTGGATGAGGAGTTCAACA)
and SMB5549 (5′-GTGCTCCTTCATCTCGGG). The reaction used Power SYBR
Green (Applied Biosystems) in an ABI Prism 7000. Initial denaturation was at 95 °C
for 10 min followed by 40 cycles of amplification with 15 s at 95 °C, and 1 min at
60 °C. Data were analyzed using ABI 7000 SDS software (v1.2.3) and normalized
using the ΔΔCT method (60). RNA slot blot analysis was performed as described
previously (36). The LRV1 copy number per cell was estimated in comparison with
a standard curve generated using DNA from a plasmid bearing the LRV1 capsid
gene (B6760, pBSKLRV1-4) and the average yield of RNA per cell across multiple
L. guyanensis RNA preparations (5.12 ± 1.17 μg/107 cells; n = 34).
Isolation of LRV1+ and LRV1− Clonal Lines by Brief Treatment with 2CMA.
LgyLRV1+ parasites were grown for one passage in media containing
25 μg/mL nourseothricin (Werner BioAgent) to verify the presence of the
integrated luciferase (LUC) gene (54). Cells were then grown one passage in
the absence of nourseothricin, and inoculated into Schneider’s media at a
concentration of 2 × 105 cells/mL into media containing 10 μM 2CMA.
Growth was measured and LRV1 quantitated by capsid flow cytometry. At
various times, cells were either plated directly, or transferred to drug-free
media, and allowed to grow an additional six cell doublings before plating.
For both, the semisolid M199 media contained 50 μg/mL nourseothricin, and
cells were diluted so that no more than ∼100 colonies were obtained per plate.
Macrophage Infections, Cytokine Assays, and Mouse Infection. Infections of
C57BL/6 mouse bone marrow-derived macrophages and cytokine assays were
performed as previously described (7, 10). Poly I:C was obtained from Invi-
vogen and used at 2 μg/mL. For mouse infections, 5- to 6-wk-old C57BL/6
mice were purchased from Jackson Laboratories. Parasites were grown into
stationary phase (2 full days) and 106 parasites were injected on the plantar
aspect of the left foot. Measurement of footpad swelling was performed
weekly using a Vernier caliper. Parasite numbers were assessed by lumi-
nescence of an integrated firefly luciferase reporter, measured using an IVIS
100 instrument as described previously (7, 54) and analyzed with Living
Image software v2.60 (Perkin-Elmer).
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Fig. S1. Structures of compounds showing activity against LRV1 related to adenosine.
Fig. S2. Inhibition results ordered by effects on relative LRV1 (A) or Leishmania guyanensis growth (B). Dashed lines show the WT control growth rate (red) or
LgyLRV1+ or LgyLRV1− capsid levels (blue).
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Fig. S3. LRV1 inhibition by 2CMA is insensitive to exogenous adenine and does not show synergy with allopurinol. (A) Plot of growth rate of LgyLRV1+ (●) or
LRV1 capsid levels (○) after 48-h propagation in increasing concentrations of allopurinol. LRV1 percentages were calculated relative to untreated controls.
(B) As in A, but with APP. (C) Effect of increasing concentrations of adenine on LgyLRV1+ treated with 100 μM 2CMA for six cell doublings (○, dashed line) or
without 2CMA (●, solid line). LgyLRV1− (●) is shown for a reference without adenine. (D) The EC50 for 2CMA inhibition of LRV1 after 48 h is unaltered in the
presence of allopurinol. The geometric mean capsid intensity is plotted relative to an untreated control. None (●, solid line), 0.1 μM (■, solid line), 1 μM (●,
dashed line), 10 μM (■, dashed line), and 100 μM (○, dashed line). Results from a single experiment are shown, other than C (n = 3).
Kuhlmann et al. www.pnas.org/cgi/content/short/1619114114 2 of 8
Fig. S4. Active site model for L. guyanensis RDRP. (A) Overall structural alignment of the Lgy LRV1 RDRP core domain’s predicted structure (green) to a crystal
structure of the HCV RDRP [light blue; PDB ID code 4WTI (62)] created with the University of California, San Francisco Chimera MatchMaker tool (63). For clarity,
only the portion of the HCV RDRP (residues 103–422) that corresponds to the LRV1 RDRP core is shown. The HCV RDRP structure contained bound RNA and
GDP. The GDP is shown in this figure to locate the NTP binding pocket. The L. guyanensis LRV1 RDRP structure was predicted using the intensive method on the
PHYRE2 web service (64), which yielded a high-confidence (≥90%) region between residues 337 and 660. Given just this core region, PHYRE2 produced a very
high-confidence structure (100% confidence over 94% of residues) with an active site very similar to the HCV structure. (B) Predicted structure of the nucleotide
binding pocket in the LRV1 RDRP. The GDP molecule from A is shown for clarity. Surface colored yellow represents the locations of residues forming a binding
site predicted by the 3DLigandSite server with high confidence (average MAMMOTH score 29.7, where ≥7 is significant) (65). Areas colored green mark
residues that, when mutated in the HCV RDRP, confer resistance to the 2′-C-methyl family of nucleoside analogs (50, 66, 67). The “Rotamers” tool in University
of California, San Francisco Chimera was used to fix side-chains given unfavorable conformations by the PHYRE2 server (68). (C) Table of predicted binding site
residues in LgyM4147 LRV1 RDRP and their corresponding residues in the HCV RDRP. Substitutions shown in bold confer resistance to 2′-C-methyl nucleoside
analogs in HCV RDRP (50, 66, 67).
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Table S2. Parasite growth and LRV1 levels in response to test compounds
Compound Abbr.
Stock
(mM) Solvent
Tested
(μM)
Density
(cells/mL)
Percent
control
LRV1
capsid
(geometric
mean FU)
Percent
control
LRV1
rank
(Fig.
S2A)
Growth
rank
(Fig.
S2B)
2′C-methyadenosine E6/2CMA 50 DMSO 100 1.22E+7 72 19 7 1 1*
2′C-methyl-7-deaza-
adenosine
7d2CMA 100 DMSO 100 3.38E+6 20 27 10 2 2*
CA-074-Me CP3 25 DMSO 50 1.00E+07 60 83 31 3 31
Allopurinol ALL 50 DMSO 100 4.06E+5 2 90 34 4 6
Chembridge 5670488 CB27 50 DMSO 100 4.59E+6 27 91 34 5 16
e64d CP2 5 DMSO 10 1.52E+07 90 97 37 6 50
NITD008 NITD008 50 DMSO 1 1.02E+7 61 98 37 7 32
Chembridge 5141196 CB31 50 DMSO 100 1.05E+7 62 108 41 8 33
Chembridge 5315625 CB17 50 DMSO 100 2.08E+7 123 113 42 9 72
R-1479 R-1479 50 DMSO 100 1.23E+7 73 114 43 10 43
Entecavir ETV 50 DMSO 100 1.77E+7 105 119 45 11 60
APP APP 50 DMSO 50 1.12E+6 7 119 45 12 12
Celgosivir Celgosivir 50 DMSO 10 1.09E+7 65 124 47 13 34
e64 CP1 25 DMSO 50 1.80E+07 107 153 58 14 63
T-705 T-705 50 DMSO 100 1.13E+7 67 161 60 15 35
Foscarnet Fosc 50 DMSO 100 9.50E+6 56 162 61 16 27
2′C-Methylcytidine 2CMC 100 DMSO 100 1.73E+7 103 162 61 17 58
Ribavirin Rib 50 Water 100 2.21E+6 13 162 61 18 13
PSI-7977 PSI-7977 50 DMSO 100 1.25E+7 74 163 61 19 44
R-7128 R-7128 50 DMSO 100 1.27E+7 76 175 66 20 45
Chembridge 5676375 CB30 50 DMSO 100 6.93E+6 41 181 68 21 21
Didanosine ddi 50 DMSO 100 1.80E+7 107 182 68 22 62
Chembridge 5482485 CB19 50 DMSO 100 2.18E+7 129 183 69 23 73
Chembridge 5323146 CB18 50 DMSO 100 2.66E+7 158 186 70 24 81
Chembridge 5675149 CB29 50 DMSO 100 9.57E+6 57 187 71 25 28
Chembridge 5671073 CB28 10 DMSO 20 1.46E+7 87 189 71 26 47
Chembridge 7978592 CB39 50 DMSO 100 3.77E+6 22 189 71 27 14
Chembridge 5141214 CB4 50 DMSO 100 1.88E+7 112 190 72 28 68
Chembridge 5788245 CB33 25 DMSO 50 1.17E+7 69 192 72 29 39
Zidovudine AZT 50 Water 100 1.81E+7 107 196 74 30 64
Ganciclovir Ganc 20 DMSO 40 9.78E+6 58 198 75 31 229
Chembridge 5106522 CB1 50 DMSO 100 4.98E+6 30 199 75 32 18
Chembridge 5141608 CB13 50 DMSO 100 1.92E+7 114 199 75 33 69
Chembridge 5492915 CB23 10 DMSO 100 1.52E+7 90 202 76 34 51
Chembridge 5790637 CB36 50 DMSO 100 1.19E+7 71 203 77 35 40
Chembridge 5141597 CB9 50 DMSO 100 1.75E+7 104 206 77 36 59
Tenofovir TDF 50 DMSO 100 8.90E+6 53 206 78 37 25
Chembridge 5584034 CB25 50 DMSO 100 1.50E+7 89 212 80 38 49
Chembridge 5312810 CB16 10 DMSO 20 4.46E+6 27 212 80 39 15
Chembridge 5489087 CB21 50 DMSO 100 1.57E+7 93 213 80 40 52
Chembridge 5789784 CB34 25 DMSO 50 1.16E+7 69 214 81 41 38
Chembridge 5668881 CB26 25 DMSO 50 1.49E+7 89 215 81 42 48
Chembridge 5141262 CB6 50 DMSO 100 1.61E+7 96 215 81 43 55
Chembridge 5790716 CB37 50 DMSO 100 7.91E+6 47 216 81 44 22
Chembridge 5487823 CB20 50 DMSO 100 2.03E+7 121 216 81 45 70
Chembridge 5144558 CB14 50 DMSO 100 2.24E+7 133 217 82 46 77
Stavudine d4T 50 EtOH 100 1.60E+7 95 220 83 47 54
Chembridge 5141213 CB3 50 DMSO 100 1.80E+7 107 220 83 48 61
Chembridge 5493580 CB24 50 DMSO 20 1.21E+7 72 222 84 49 42
Chembridge 5141604 CB11 50 DMSO 100 2.24E+7 133 223 84 50 76
Chembridge 5141605 CB12 50 DMSO 100 2.56E+7 152 225 85 51 80
Chembridge 5237407 CB15 50 DMSO 100 1.82E+7 108 227 86 52 66
2′-Fluoro-2′-deoxycytidine E1 50 DMSO 100 2.21E+7 132 230 87 53 74
Chembridge 5491596 CB22 50 DMSO 100 1.62E+7 97 232 87 54 56
5-Fluoro-5′-deoxyuridine 5F5D 50 DMSO 100 4.71E+6 28 234 88 55 17
2′-fluoro-2′-deoxyuridine E2 50 DMSO 100 2.22E+7 132 234 88 56 75
Chembridge 7972230 CB38 50 DMSO 100 6.67E+6 40 236 89 57 20
Mycophenolic acid MMA 50 DMSO 1 4.55E+5 3 238 90 58 7
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Table S2. Cont.
Compound Abbr.
Stock
(mM) Solvent
Tested
(μM)
Density
(cells/mL)
Percent
control
LRV1
capsid
(geometric
mean FU)
Percent
control
LRV1
rank
(Fig.
S2A)
Growth
rank
(Fig.
S2B)
Lamivudine 3TC 50 DMSO 100 9.20E+6 55 242 91 59 26
8-Azahypoxanthine 8AH 50 DMSO 100 1.29E+7 77 251 95 60 46
5-Azauracil 5AU 50 DMSO 100 1.13E+7 67 252 95 61 36
2′C-Methyguanosine E7 50 DMSO 100 2.25E+7 133 252 95 62 78
2′-Fluoro-2′-deoxyinosine E5 50 DMSO 100 2.41E+7 143 255 96 63 79
Chembridge 5705708 CB32 50 DMSO 100 8.69E+6 52 255 96 64 24
2′-Fluoro-2′-
deoxyadenosine
E3 50 DMSO 100 2.07E+7 123 257 97 65 71
Sulfaguanidine None 50 DMSO 100 1.15E+7 68 260 98 66 37
8-Azaguanine 8AG 50 DMSO 100 5.68E+6 34 264 100 67 19
6-Azauracil 6AU 50 DMSO 100 1.20E+7 71 271 102 68 41
3′-Azido-3′-hydroxyethyl
cyclobutyl adenine
E8 50 DMSO 100 1.86E+7 111 277 104 69 67
3′-Azido-3′-hydroxyethyl
cyclobutyl adenine
E9 50 DMSO 100 1.58E+7 94 279 105 70 53
Chembridge 5790592 CB35 50 DMSO 100 1.00E+5 1 287 108 71 3
3′-Hydroxyethyl
cyclobutyl adenine
E10 50 DMSO 100 1.82E+7 108 290 109 72 65
2’-fluoro-2’-
deoxyguanosine
E4 50 DMSO 100 1.68E+7 100 326 123 73 57
Chembridge 5135608 CB2 50 DMSO 100 1.55E+5 1 460 173 74 4
Chembridge 5141601 CB10 50 DMSO 100 5.72E+5 3 502 189 75 8
5-Fluorouracil 5FU 50 DMSO 100 9.05E+5 5 512 193 76 11
Chembridge 5141274 CB8 50 DMSO 100 2.02E+5 1 547 206 77 5
Chembridge 5141245 CB5 50 DMSO 100 8.73E+5 5 603 227 78 10
Cidofovir CDF 10 40% DMSO,
0.1 mM
NaOH
40 9.99E+6 59 637 240 79 30
Chembridge 5141271 CB7 50 DMSO 100 5.85E+5 3 650 245 80 9
Acyclovir ACY 30 DMSO 120 8.55E+6 51 687 259 81 23
LgyLRV1+ CONTROL LRV1+ N/A N/A N/A 1.68E+07 100 265 100 N/A N/A
LgyLRV1− CONTROL LRV1− N/A N/A N/A 1.42E+07 85 9 3 N/A N/A
Compound names and abbreviations (Table S1) are provided in column 1. Inhibitors were dissolved and used as indicated in column 2. Parasite density was
measured after 2 d in culture and normalized to the percent growth of the diluent-treated control in column 3. LRV1 capsid signal was assessed at the same
time as growth in column 4. Columns 5 and 6 provide the rank position for each compound as depicted in Fig. S2. Red shading represents inhibition of
L. guyanensis. Green shading represents inhibition of LRV1. Yellow shading denotes control parameters. N/A, not applicable.
*Actual rank: 1 = 42, 2 = 12.
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